Pharmacogenomics of infliximab therapy, impact of TNFRSF1A and TNFRSF1B gene polymorphisms

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00072502" target="_blank" >RIV/00216224:14110/13:00072502 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/13:E0103650

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Pharmacogenomics of infliximab therapy, impact of TNFRSF1A and TNFRSF1B gene polymorphisms

Popis výsledku v původním jazyce

Introduction. Anti-TNF alpha monoclonal antibodies present an effective way of treating Crohn's disease ( CD). Despite their high benefits, there is about 30% rate of a primary non-response. The main target of infliximab is the soluble form of TNF alpha,which blocks its pro-inflammatory activity and the induction of apoptosis via the TNF alpha membrane form. The activity of TNF alpha and balance between its pro-inflammatory and pro-apoptotic effect is mediated by the interaction with its receptors (TNFR). Mechanisms of signaling via TNF alpha-TNFR interaction has been recently intensively studied from a perspective of selecting appropriate candidates for the infliximab treatment. Aim. The aim of this study was to evaluate whether polymorphisms in TNFRSF1A and TNFRSF1B genes influence the efficacy of the infliximab therapy. Methods. A total of 116 Caucasian CD patients treated with infliximab were genotyped.

Název v anglickém jazyce

Pharmacogenomics of infliximab therapy, impact of TNFRSF1A and TNFRSF1B gene polymorphisms

Popis výsledku anglicky

Introduction. Anti-TNF alpha monoclonal antibodies present an effective way of treating Crohn's disease ( CD). Despite their high benefits, there is about 30% rate of a primary non-response. The main target of infliximab is the soluble form of TNF alpha,which blocks its pro-inflammatory activity and the induction of apoptosis via the TNF alpha membrane form. The activity of TNF alpha and balance between its pro-inflammatory and pro-apoptotic effect is mediated by the interaction with its receptors (TNFR). Mechanisms of signaling via TNF alpha-TNFR interaction has been recently intensively studied from a perspective of selecting appropriate candidates for the infliximab treatment. Aim. The aim of this study was to evaluate whether polymorphisms in TNFRSF1A and TNFRSF1B genes influence the efficacy of the infliximab therapy. Methods. A total of 116 Caucasian CD patients treated with infliximab were genotyped.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers, Olomouc: Palacky University

ISSN

1213-8118

e-ISSN

—

Svazek periodika

157

Číslo periodika v rámci svazku

Supplementum 1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

4

Strana od-do

"S75"-"S78"

Kód UT WoS článku

000324728600007

EID výsledku v databázi Scopus

—